In the second part of their discussion at ASCO GU 2025, Dr. Kan Gong (Peking University First Hospital) and Dr. Eric Jonasch (MD Anderson Cancer Center) examined the evolving role of Belzutifan in advanced renal cell carcinoma (RCC) and VHL-associated tumors. The LightSpark 015 study reinforced its efficacy in RCC, though responses in pheochromocytoma (PGL) remain uncertain. They debated its future as a monotherapy and its potential in combination with TKIs or immunotherapy. Ongoing trials will determine its best use in treatment sequencing and patient selection.
